These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Protective effects of PACAP in ischemia. Reglodi D; Vaczy A; Rubio-Beltran E; MaassenVanDenBrink A J Headache Pain; 2018 Mar; 19(1):19. PubMed ID: 29500688 [TBL] [Abstract][Full Text] [Related]
3. Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models. Maasz G; Zrinyi Z; Reglodi D; Petrovics D; Rivnyak A; Kiss T; Jungling A; Tamas A; Pirger Z Dis Model Mech; 2017 Feb; 10(2):127-139. PubMed ID: 28067625 [TBL] [Abstract][Full Text] [Related]
4. PACAP as a neuroprotective factor in ischemic neuronal injuries. Shioda S; Nakamachi T Peptides; 2015 Oct; 72():202-7. PubMed ID: 26275482 [TBL] [Abstract][Full Text] [Related]
5. Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model. Lamine A; Létourneau M; Doan ND; Maucotel J; Couvineau A; Vaudry H; Chatenet D; Vaudry D; Fournier A Neuropharmacology; 2016 Sep; 108():440-50. PubMed ID: 26006268 [TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of PACAP against paraquat-induced oxidative stress in the Drosophila central nervous system. Hajji K; Mteyrek A; Sun J; Cassar M; Mezghani S; Leprince J; Vaudry D; Masmoudi-Kouki O; Birman S Hum Mol Genet; 2019 Jun; 28(11):1905-1918. PubMed ID: 30715303 [TBL] [Abstract][Full Text] [Related]
7. Effect of PACAP in central and peripheral nerve injuries. Tamas A; Reglodi D; Farkas O; Kovesdi E; Pal J; Povlishock JT; Schwarcz A; Czeiter E; Szanto Z; Doczi T; Buki A; Bukovics P Int J Mol Sci; 2012; 13(7):8430-8448. PubMed ID: 22942712 [TBL] [Abstract][Full Text] [Related]
8. Effects of PACAP on Dry Eye Symptoms, and Possible Use for Therapeutic Application. Shioda S; Takenoya F; Hirabayashi T; Wada N; Seki T; Nonaka N; Nakamachi T J Mol Neurosci; 2019 Jul; 68(3):420-426. PubMed ID: 29931503 [TBL] [Abstract][Full Text] [Related]
9. Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide. Bourgault S; Vaudry D; Dejda A; Doan ND; Vaudry H; Fournier A Curr Med Chem; 2009; 16(33):4462-80. PubMed ID: 19835562 [TBL] [Abstract][Full Text] [Related]
10. Role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the action of ginsenoside Rh2 against beta-amyloid-induced inhibition of rat brain astrocytes. Shieh PC; Tsao CW; Li JS; Wu HT; Wen YJ; Kou DH; Cheng JT Neurosci Lett; 2008 Mar; 434(1):1-5. PubMed ID: 18313848 [TBL] [Abstract][Full Text] [Related]
11. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Reglodi D; Kiss P; Lubics A; Tamas A Curr Pharm Des; 2011; 17(10):962-72. PubMed ID: 21524257 [TBL] [Abstract][Full Text] [Related]
12. [Pituitary adenylate cyclase-activating polypeptide]. Gonzalez BJ; Basille M; Vaudry D; Fournier A; Vaudry H Ann Endocrinol (Paris); 1998 Dec; 59(5):364-405. PubMed ID: 9949891 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of PACAP for neurodegenerative diseases. Yang R; Jiang X; Ji R; Meng L; Liu F; Chen X; Xin Y Cell Mol Biol Lett; 2015 Jun; 20(2):265-78. PubMed ID: 26204407 [TBL] [Abstract][Full Text] [Related]